Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II/III study of Onco TCS passes safety review

Aug. 24, 2001

Roche discloses antiproliferative derivatives useful for the treatment of solid tumors

Aug. 23, 2001

Corixa and GSK submit complete response to FDA for Bexxar

Aug. 23, 2001

Praecis announces meeting date with FDA regarding Plenaxis NDA

Aug. 23, 2001

Two antiangiogenesis agents from EntreMed receive orphan drug status

Aug. 23, 2001

Xenova and QLT sign licensing agreement for XR-9576

Aug. 22, 2001

Abgenix and Agensys sign cancer immunotherapy collaboration

Aug. 22, 2001

Addition of ZD-1839 to conventional maintenance therapy being evaluated in NSCLC patients

Aug. 22, 2001

EGFR and HER-2 tyrosine kinase inhibitors with in vivo antitumor activity reported

Aug. 22, 2001

Combretastatin significantly potentiates the antitumor action of radioimmunotherapy

Aug. 22, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...